Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.15% is 29% above its 5-year average of -32.38%, near the high end of its 5-year range (-72.66%–-8.61%).
83.88% below its 12-month average of -12.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.23%.
RETURN ON ASSETS (ROA)
-23.15%
RETURN ON ASSETS (ROA) AVG TTM
-12.59%
RETURN ON ASSETS (ROA) AVG 3Y
-25.36%
RETURN ON ASSETS (ROA) AVG 5Y
-32.38%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-83.88%
CURRENT VS 3Y AVG
+8.71%
CURRENT VS 5Y AVG
+28.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.45%
median of 501 covered companies
CURRENT VS SECTOR MEDIAN
+12.48%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$867.60M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$856.30M
Return on Assets (ROA)
-32.46%
TTM Avg
-61.56%
3Y Avg
-55.11%
5Y Avg
-72.90%
Market Cap
$852.55M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$844.28M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$837.43M
Return on Assets (ROA)
-9.67%
TTM Avg
-10.63%
3Y Avg
-19.71%
5Y Avg
-38.52%
Market Cap
$903.13M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$819.44M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
Market Cap
$915.95M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $867.60M | -23.15% | -12.59% | -25.36% | -32.38% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | -32.46% | -61.56% | -55.11% | -72.90% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -24.96% | -29.43% | -70.30% | -70.30% |
| Alumis Inc. (ALMS)vs › | $844.28M | -78.30% | -72.68% | -105.45% | -105.45% |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -9.67% | -10.63% | -19.71% | -38.52% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -22.62% | -55.95% | -57.94% | -46.38% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -8.70% | 6.33% | -16.09% | -46.82% |
| Bioventus Inc. (BVS)vs › | $915.95M | 8.09% | -0.64% | -8.03% | -4.54% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 4.06% | 3.72% | 3.23% | 2.82% |
ROA
-23.1%
ROE
-33.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -8.61% |
| 2024-12-31 | -16.57% |
| 2023-12-31 | -44.56% |
| 2022-12-31 | -31.69% |
| 2021-12-31 | -20.19% |
| 2020-12-31 | -72.66% |
| 2019-12-31 | -72.26% |
